Measurement of Serum Antibody Titer against Measles in a group of Adults Receiving Measles-Rubella Mass Vaccination

• Background: Measles vaccination in Iran is an expanded program. Since 1973- 2002, all infants have received live attenuated measles vaccine (0.5 ml, subcutaneous, A.I.K strain) at the 9th and 15th months of life. Before 2002, we confronted outbreaks of measles in previously vaccinated adults from...

Full description

Bibliographic Details
Published in:	مجله دانشکده پزشکی اصفهان
Main Authors:	Alireza Emami Naeini, Negar Ghazavi, Sahar Emami Naeini
Format:	Article
Language:	Persian
Published:	Isfahan University of Medical Sciences 2011-03-01
Subjects:	Measles Antibody titer Rubella
Online Access:	http://jims.mui.ac.ir/index.php/jims/article/view/677

Similar Items

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study
by: The MMR-162 Study Group
Published: (2018-12-01)

Analysis of Measles and Rubella Immunoglobulin G Titers in COVID-19 Patients
by: Başbulut E, et al.
Published: (2024-11-01)

A Survey of Vaccine-Induced Measles IgG Antibody Titer to Verify Temporal Changes in Response to Measles Vaccination in Young Adults
by: Hiraku Sasaki, et al.
Published: (2019-09-01)

Manifestations of the Epidemic Process of Measles and Rubella at the Present Stage
by: A. A. Pozdnyakov, et al.
Published: (2018-10-01)

Coverage of the Measles-Rubella mass camping vaccination in southern Tehran, Iran
by: Majd Zadeh SR, et al.
Published: (2005-04-01)

Collective Immunity to the Measles, Mumps, and Rubella Viruses in the Kyrgyz Population
by: Anna Yurievna Popova, et al.
Published: (2025-02-01)

INFLUENCE OF POPULATION IMMUNITY PECULIARITIES ON THE STRUCTURE OF MEASLES AND RUBELLA PREVALENCE
by: A. P. Toptygina, et al.
Published: (2018-11-01)

Measles， rubella， and mumps antibody seroprevalence among the children aged 18 years and younger in Karamay City， Xinjiang Uygur Autonomous Region
by: WU Meili, et al.
Published: (2025-03-01)

Epidemiology of Laboratory Confirmed Measles and Rubella Outbreaks in Rajasthan
by: Pooja Choudhary, et al.
Published: (2018-08-01)

Serosurveillance for Measles and Rubella
by: Allison M. Brady, et al.
Published: (2024-07-01)

DETECTION OF MEASLES AND RUBELLA ANTIBODIES IN DRIED BLOOD SPOTS
by: Stefka Krumova, et al.
Published: (2018-12-01)

A Serological Survey of Measles and Rubella Antibodies among Different Age Groups in Eastern China
by: Rui Yan, et al.
Published: (2024-07-01)

Global Status Report for the Verification of Measles and Rubella Elimination, 2022
by: Patrick O’Connor, et al.
Published: (2024-08-01)

Persistence of Antibodies against Measles, Mumps, and Rubella after the Two-Dose MMR Vaccination: A 7-Year Follow-Up Study
by: Nasiri Sarawanangkoor, et al.
Published: (2024-07-01)

Lessons for sustaining the elimination of measles, rubella, and congenital rubella syndrome in the Caribbean
by: Tracy Evans-Gilbert, et al.
Published: (2024-12-01)

Topical issues of vaccination and epidemiological surveillance over measles and rubella in Ukraine.
by: G. M. Daragan, et al.
Published: (2018-04-01)

Two cases of measles after vaccination with measles mumps and rubella combined live attenuated vaccine
by: SHEN Jinhua, et al.
Published: (2022-05-01)

Progress of Measles and Rubella Surveillance in the Context of Measles Elimination in the WHO Eastern Mediterranean Region, 2019–2022
by: Muhammad Farid, et al.
Published: (2024-11-01)

A journey worth taking: global eradication of measles, rubella and congenital rubella syndrome
by: Jon Kim Andrus, et al.
Published: (2025-12-01)

ENHANCING KNOWLEDGE AND AWARENESS FOR MEASLES AND RUBELLA ELIMINATION TO PREVENT CONGENITAL RUBELLA SYNDROME IN KULON PROGO AND GUNUNGKIDUL REGENCIES
by: Elisabeth Siti Herini, et al.
Published: (2024-11-01)

Utility of serological screening for measles, mumps and rubella in immunocompromised patients
by: L Sticchi, et al.
Published: (2019-12-01)

On the Path to Measles and Rubella Elimination Following Rubella-Containing Vaccine Introduction, 2000–2023, Namibia
by: Balcha G. Masresha, et al.
Published: (2024-08-01)

Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin
by: Andrea A. Berry, et al.
Published: (2017-07-01)

Sustaining measles and rubella elimination through the Regional Monitoring and Re-Verification Commission in the Americas
by: Jon K. Andrus, et al.
Published: (2024-12-01)

Serosurvey of anti‐rubella and anti‐measles IgG antibodies in young females in Jahrom, southern west Iran in 2012: A review of literature of the serological profile in Iran
by: Najmeh Mojarad, et al.
Published: (2024-03-01)

The State of Specific Immunity to Measles and Rubella Virus in Newborns and their mothers
by: N. T. Tikhonova, et al.
Published: (2017-12-01)

Measles and Rubella Diagnostic and Classification Challenges in Near- and Post-Elimination Countries
by: Thomas D. Filardo, et al.
Published: (2024-06-01)

Safety of antibodies to measles, mumps, rubella and diphtheria in patients with juvenile idiopathic arthritis
by: I. V. Fridman, et al.
Published: (2021-07-01)

The impact of Measles-Rubella vaccination on the morbidity and mortality from Congenital Rubella Syndrome in 92 countries
by: Emilia Vynnycky, et al.
Published: (2019-02-01)

Development of measles‑rubella surveillance health information system in the working area of health center tanjung selor, bulungan district
by: Andi C. Pertiwi, et al.
Published: (2023-12-01)

Accelerating Global Measles and Rubella Eradication—Saving Millions of Lives, Preventing Disability, and Averting the Next Pandemic
by: David N. Durrheim, et al.
Published: (2024-06-01)

Coverage and predictors of full measles-rubella immunization among children aged 24–59 months in Northern Ghana: a post measles outbreak assessment
by: Abdul Gafaru Mohammed, et al.
Published: (2025-05-01)

Analysis of the suspected cases of measles and rubella in Pudong New Area of Shanghai， 2013‒2022
by: WANG Xiao, et al.
Published: (2024-06-01)

Measles Virus Neutralizing Antibody Response and Durability Two Years after One or Two Doses of Measles–Mumps–Rubella Vaccine among Young Seronegative Healthcare Workers
by: Byungki Jang, et al.
Published: (2022-10-01)

Global challenges and solutions to achieving and sustaining measles and rubella elimination
by: Natasha S. Crowcroft, et al.
Published: (2024-12-01)

Measles and rubella in the North-West of Russia in period of elimination
by: M. A. Bichurina, et al.
Published: (2021-12-01)

Building Quality Control for Molecular Assays in the Global Measles and Rubella Laboratory Network
by: Bettina Bankamp, et al.
Published: (2024-07-01)

STATE OF MEASLES, RUBELLA AND MUMPS IN THE SARATOV REGION IN 2001—2013 YEARS
by: T. N. Buchkova, et al.
Published: (2015-08-01)

Serological status of measles, mumps, and rubella antibodies in HIV-positive women of childbearing age at a referral hospital in Iran
by: Sara Ghaderkhani, et al.
Published: (2025-04-01)

Herd Immunity to the Measles, Mumps and Rubella Viruses Among the Belgradian Population in May, 2024
by: Anna Y. Popova, et al.
Published: (2025-06-01)